Therefore, since they target different antigens on MM cells, it seemed exciting to explore the combination of them that the Phase 1b/2 RedirecTT-1 study (NCT04586426) is evaluating in RRMM patients who have been exposed to a PI, IMiD, and anti-CD38 mAb [60]. This evidence concerns the gene CD38 and Miyoshi myopathy.